InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Dr. Clarissa Souza, a board-certified veterinary dermatologist and head of the dermatology and otology service at the University of Illinois Veterinary Teaching Hospital in Urbana. Dr. Clarissa Souza, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results